Speciality: Oncology
Description:
Welcome to an insightful discussion on the critical topic of Cost Burden and Burden of Hospitalization for Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) Patients. Esteemed experts Dr. Pawan Kumar Singh, Dr. Roshan Dikshit, Dr. Manisha Jain, and Dr. Avriti Baveja delve into the multifaceted challenges faced by patients and healthcare systems. The conversation sheds light on the financial, emotional, and logistical strains of prolonged hospitalization, recurring treatments, and the socioeconomic disparities impacting access to advanced therapies. This session is a must-watch for healthcare professionals, policymakers, and caregivers seeking to understand the real-world implications of managing R/R ALL.
In the second segment, the panel explores actionable strategies to alleviate the burden on patients and families. Dr. Singh emphasizes the importance of cost-effective treatment protocols, while Dr. Dikshit highlights innovations in outpatient care models to reduce hospitalization frequency. Dr. Jain and Dr. Baveja further discuss the role of patient advocacy, insurance reforms, and government policies in bridging gaps in care. Their collective expertise provides a comprehensive roadmap to address systemic inefficiencies and improve the quality of life for R/R ALL patients.
Concluding on a hopeful note, the experts underscore the need for collaborative efforts between clinicians, researchers, and policymakers to drive sustainable change. The discussion not only raises awareness but also inspires actionable solutions to mitigate the economic and emotional toll of R/R ALL. Viewers are encouraged to watch the full video to gain deeper insights into this pressing issue and stay tuned for future discussions featuring these thought leaders in oncology and hematology.
See More Webinars @ Hidoc Webinars
1.
Stem Cell Selection Unneeded for SSc Transplant Therapy?
2.
Lung Transplant for Lung Cancer: Promising, in Rare Cases
3.
Rural-urban disparities seen in cervical cancer
4.
Obesity linked to subsequent neoplasms in childhood cancer survivors
5.
New policy review highlights the importance of health-related quality of life in advanced cancer
1.
Empowering Oncology with Data: Cloud Security, Real-World Evidence, and Clinical Insights
2.
Transplant Oncology and Anti-Cancer Immunosuppressants: The Evolution of a Paradigm in Cancer Care
3.
Is AI The New Radiologist For Breast MRI?
4.
Pediatric Oncology at the Cutting Edge: From Early Diagnosis to Lifesaving Therapies
5.
Bone Marrow Regeneration in Hematologic Recovery
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part VI
2.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
3.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III
4.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation